登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C21H24N4O2
化学文摘社编号:
分子量:
364.44
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
产品名称
IKK-2 Inhibitor VIII, The IKK-2 Inhibitor VIII, also referenced under CAS 406208-42-2, controls the biological activity of IKK-2. This small molecule/inhibitor is primarily used for Inflammation/Immunology applications.
SMILES string
N1CCC(CC1)c2c(c(nc(c2)c3c(cccc3O)OCC4CC4)N)C#N
InChI
1S/C21H24N4O2/c22-11-16-15(14-6-8-24-9-7-14)10-17(25-21(16)23)20-18(26)2-1-3-19(20)27-12-13-4-5-13/h1-3,10,13-14,24,26H,4-9,12H2,(H2,23,25)
InChI key
DYVFBWXIOCLHPP-UHFFFAOYSA-N
assay
≥95% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
protect from light
color
yellow
solubility
DMSO: 10 mg/mL
shipped in
wet ice
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
Cell permeable: yes
Primary Target
IKK-2
IKK-2
Product does not compete with ATP.
Reversible: no
Target IC50: 8.5 and 250 nM for IKK-2 and IKK-1, respectively
Disclaimer
Toxicity: Irritant (B)
General description
A cell-permeable piperidinyl-pyridine compound that acts as a selective inhibitor of IKK-2 activity (IC50 = 8.5 and 250 nM for IKK-2 and IKK-1, respectively) with little effect towards IKK-3, Syk, and MKK4 (IC50 >20 µM). Exhibits good aqueous solubility (0.12 mg/ml in pH 7.4 isotonic buffer) and potent activity in various cellular assays in vitro (IC50<150 nM). Shown to be orally bioavailable both in rats and mice (BA = 60% and 16%, respectively) and effectively inhibit arachidonic acid-induced swelling in a murine ear edema model in vivo.
Other Notes
Murata, T., et al. 2004. Bioorg. Med. Chem. Lett.14, 4019.
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Sonication is required for complete solubilization.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Jin Hua Liang et al.
mBio, 12(4), e0153021-e0153021 (2021-07-21)
Epstein-Barr virus (EBV) is associated with 200,000 cancers annually, including B-cell lymphomas in immunosuppressed hosts. Hypomorphic mutations of the de novo pyrimidine synthesis pathway enzyme cytidine 5' triphosphate synthase 1 (CTPS1) suppress cell-mediated immunity, resulting in fulminant EBV infection and
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持